Froelich MF, et al. - In metastatic colorectal cancer (mCRC), researchers evaluated the prognostic ability of pre-therapeutic computed tomography (CT) attenuation of liver metastases for overall survival (OS) by analyzing the data of patients with histologically confirmed mCRC who received fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) with either cetuximab or bevacizumab. The results from the open-label, randomized, prospective phase-3 FIRE-3 trial indicate that increased mean baseline CT attenuation of liver metastases might recognize mCRC patients with longer OS and better tumor response. Findings suggested a significant association of mean attenuation ≥61.62 HU with increased early tumor shrinkage and increased depth of response.